You're not just running trials—you’re racing timelines, navigating regulations, and chasing precision. This edition gives you the strategic edge to move faster, launch smarter, and avoid costly setbacks across emerging and established markets.
MedTech
You’re not just running trials—you’re racing timelines, navigating regulations, and chasing precision. This edition gives you the strategic edge to move faster, launch smarter, and avoid costly setbacks across emerging and established markets.
Australia is making it easier and faster for pharmaceutical and biologic sponsors to bring new therapies to market. The Therapeutic Goods Administration (TGA) has introduced enhanced regulatory pathways—Priority Review, Provisional Approval, and Reliance Routes—to speed up approvals, especially for serious conditions and innovative treatments.
With improvements in electronic submissions, mutual GMP recognition, and greater alignment with international regulators, the country is positioning itself as a strategic hub for early-phase drug development.
Brazil’s National Health Surveillance Agency (ANVISA) has unveiled its 2026–2027 Regulatory Agenda, highlighting 161 priorities across medical devices, pharmaceuticals, biologics, and other sectors. Built through public consultation and technical review, the agenda offers a forward-looking view of how the agency plans to modernize, align with international standards, and improve transparency.
For clinical trial sponsors and manufacturers, this provides a strategic signal to anticipate changes, prepare submissions accordingly, and align development timelines with Brazil’s evolving regulatory landscape.
Cartography Biosciences has received both FDA IND approval and Fast Track designation for its lead program, CBI-1214, an immunotherapy candidate targeting colorectal cancer. The therapy is based on Cartography’s proprietary discovery platform, which identifies tumor-specific antigens with high precision.
The company plans to initiate a Phase I/II trial in 2026, focused on advanced-stage colorectal cancer patients who have limited treatment options.
For sponsors and developers, this is a clear example of how early identification of novel targets and regulatory engagement can fast-track promising therapies—reinforcing the value of precision approaches in early-phase development.
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule Your First-in-Human Trial Consult.
In a U.S.-based clinical trial for cancer patients, over 50% of those who declined participation cited financial concerns—including travel, lodging, and loss of income—as their primary reason. Only 16% said they weren’t interested in participating at all.
The study reveals a striking insight: patients are willing, but the hidden costs of joining a trial remain a major barrier, even in high-income countries. While reimbursement tools and stipends exist, their inconsistent use continues to limit access.
For sponsors operating in cost-sensitive regions like Latin America or the Balkans, proactively addressing patient expenses—even in early-phase trials—can lead to faster recruitment and more inclusive data.
Montenegro is becoming an attractive destination for early-phase clinical research, but running multicenter trials in the region requires careful planning. Differences in IRB requirements, language considerations, and operational readiness across sites can create friction if not addressed early.
Effective coordination strategies include aligning ethics timelines, centralizing site communication, and streamlining processes like document translation and investigator training.
The European Commission has proposed updates to the Medical Device Regulation (MDR) that would ease requirements for certain low-risk, well-established medical devices. The plan would allow many Class I and IIa devices to stay on the market longer without immediate recertification, reducing pressure on limited notified body capacity.
The changes aim to improve regulatory efficiency while maintaining safety, with special consideration for smaller manufacturers and health system supply needs.
If adopted, the proposal could speed up access for legacy devices and lighten the regulatory load on Medtech sponsors planning pilot or feasibility studies in the EU and surrounding regions, including the Balkans.
← All Global Trial Accelerators editions · Contact bioaccess®